Rhopressa ® (netarsudil) – New drug approval
December 18, 2017 – Aerie Pharmaceuticals announced the FDA approval of Rhopressa (netarsudil) 0.02% ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension.
Download PDF
